DIA: Driving Insights to Action
Science:Life Sciences
“The relationship between an endpoint and an outcome is similar in many ways to the relationship between data and evidence,” explains Michael Lees, Head of Value, Evidence and Portfolio for Europe and Canada at Takeda Pharmaceutical Company Limited, and a program committee member for DIA’s Advancing the Science of Study Endpoints conference. “You can take a similar approach if you’re a clinical or regulatory expert: The transformation of the endpoint that’s measured in a clinical study into something that has meaning when you’re making a decision.”
Need for Value Creates Opportunity for Patients
Can Europe Optimize Healthcare Quality AND Pricing?
Rules for Successful Patient-Industry Engagement
Multiple Channels Can Share “One Medical Voice”
Advertising & Promotion: What You Can (and Can’t) Say
Could Precision Medicine Deliver “You on a Chip”?
“Enlightened Regulation” Illuminating Translational Science
Time and Place for Innovation in a Pandemic Outbreak?
SFDA Talks Drug Pricing & Shortages in Advance of MERC 2017
Translating Medical Information into Effective Communication
Tufts eClinical Study: Complexity Overrunning Technology
Post-Brexit PV in Europe “An Issue We Shouldn’t Underestimate”
CDER Director: Interest in How Patients Feel & Function
EU Clinical Trial Regulation Streamlines to "Matter of One"
The Gaps In Drug Pricing
Biosimilars’ Good News for Patients
Pace of Innovation vs. Regulation: Combination Challenge
Oligonucleotides Driving Personalized Medicine Research
Celebrating 150 Years with Better Care for Canadians
Future Science & Drug Review: FDA Closing the Gap
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
پادکست آذرخش مکری - azarakhsh mokri